IO112

**IO112** is an investigational, off-the-shelf therapeutic cancer vaccine developed by IO Biotech from its T-win platform. It contains a single arginase-1-derived peptide intended to activate and expand arginase-1-specific human T cells. The resulting T-cell response is designed to recognize arginase-1-expressing tumor cells and immunosuppressive cells in the tumor microenvironment, particularly tumor-associated macrophages and other myeloid populations, thereby promoting a more pro-inflammatory, antitumor microenvironment. IO112 is not a direct arginase enzyme inhibitor. Publicly described tumor settings include renal cell carcinoma, head and neck cancer, breast cancer, pancreatic cancer, ovarian cancer, colorectal cancer, and prostate cancer. ([iobiotech.com](https://iobiotech.com/science/programs/))

Other names

arginase-1 peptide vaccinearginase1 peptide vaccinearginase 1 peptide vaccineARG1 vaccineARG-1 vaccineARG 1 vaccine